Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Unusually active option classes on open August 4th » 09:40
08/04/20
08/04
09:40
08/04/20
09:40
PSTG

Pure Storage

$18.11 /

+ (+0.00%)

, ARCC

Ares Capital

$14.44 /

+ (+0.00%)

, ADT

ADT Inc.

$13.42 /

+ (+0.00%)

, BP

BP

$22.09 /

+ (+0.00%)

, VALE

Vale

$11.43 /

+ (+0.00%)

, AZN

AstraZeneca

$56.80 /

+ (+0.00%)

, INTC

Intel

$48.29 /

+ (+0.00%)

, PINS

Pinterest

$36.07 /

+ (+0.00%)

, MO

Altria Group

$41.00 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: Pure Storage (PSTG), Ares Capital (ARCC), ADT (ADT), ProShares VIX Short Term Futures (VIXY), BP (BP), Vale (VALE), AstraZeneca (AZN), Intel (INTC), Pinterest (PINS), and Altria Group (MO).

ShowHide Related Items >><<
VALE Vale
$11.43 /

+ (+0.00%)

PSTG Pure Storage
$18.11 /

+ (+0.00%)

PINS Pinterest
$36.07 /

+ (+0.00%)

MO Altria Group
$41.00 /

+ (+0.00%)

INTC Intel
$48.29 /

+ (+0.00%)

BP BP
$22.09 /

+ (+0.00%)

AZN AstraZeneca
$56.80 /

+ (+0.00%)

ARCC Ares Capital
$14.44 /

+ (+0.00%)

ADT ADT Inc.
$13.42 /

+ (+0.00%)

PSTG Pure Storage
$18.11 /

+ (+0.00%)

06/18/20 Deutsche Bank
Pure Storage initiated with a Hold at Deutsche Bank
06/17/20 Deutsche Bank
Pure Storage initiated with a Hold at Deutsche Bank
05/29/20 Lake Street
Pure Storage a share gainer with 'robust' subscription growth, says Lake Street
05/29/20 Northland
Pure Storage price target raised to $23 from $21 at Northland
ARCC Ares Capital
$14.44 /

+ (+0.00%)

05/07/20 Citi
Ares Capital price target raised to $15 from $13 at Citi
04/16/20 Raymond James
Ares Capital upgraded to Outperform at Raymond James on valuation
04/16/20 Raymond James
Ares Capital upgraded to Outperform from Market Perform at Raymond James
04/13/20 BofA
Ares Capital upgraded to Buy from Neutral at BofA
ADT ADT Inc.
$13.42 /

+ (+0.00%)

08/03/20 Goldman Sachs
ADT Inc. price target raised to $17 from $9 at Goldman Sachs
08/03/20 William Blair
Alarm.com downgraded at William Blair on ADT/Google overhang
08/03/20 William Blair
Alarm.com downgraded to Market Perform from Outperform at William Blair
08/03/20 Morgan Stanley
ADT Inc. price target raised to $17 from $7 at Morgan Stanley
BP BP
$22.09 /

+ (+0.00%)

07/16/20 Jefferies
BP upgraded to Buy from Hold at Jefferies
07/15/20 JPMorgan
BP price target raised to 425 GBp from 400 GBp at JPMorgan
07/14/20 Credit Suisse
BP price target lowered to 350 GBp from 360 GBp at Credit Suisse
07/01/20 Barclays
BP price target raised to 400 GBp from 380 GBp at Barclays
VALE Vale
$11.43 /

+ (+0.00%)

06/11/20 Deutsche Bank
Vale price target raised to $13 from $11 at Deutsche Bank
06/09/20 GLJ Research
Fortescue Metals upgraded to Hold from Sell at GLJ Research
06/05/20 Exane BNP Paribas
Vale upgraded to Outperform from Neutral at Exane BNP Paribas
06/03/20 UBS
Vale upgraded to Buy from Neutral at UBS
AZN AstraZeneca
$56.80 /

+ (+0.00%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
INTC Intel
$48.29 /

+ (+0.00%)

08/04/20 Jefferies
AMD price target raised to $95 from $86 at Jefferies
08/03/20 Roth Capital
MaxLinear price target raised to $35 from $30 at Roth Capital
08/03/20 Stifel
Stifel rises MaxLinear price target to $35 after completion of Home Gateway deal
07/31/20 Erste
Intel downgraded to Hold from Buy at Erste
PINS Pinterest
$36.07 /

+ (+0.00%)

08/03/20
Fly Intel: Top five analyst upgrades
08/03/20 Wedbush
Pinterest price target raised to $39 from $31 at Wedbush
08/03/20 DA Davidson
Pinterest price target raised to $28 from $19 at DA Davidson
08/03/20 JPMorgan
Pinterest price target raised to $37 from $26 at JPMorgan
MO Altria Group
$41.00 /

+ (+0.00%)

07/08/20
Fly Intel: Top five analyst downgrades
07/08/20 Barclays
Altria downgraded to Equal Weight on share losses at Barclays
07/08/20 Barclays
Altria Group downgraded to Equal Weight from Overweight at Barclays
07/07/20 Stifel
IQOS reduced exposure claim a 'win' for Philip Morris, Altria, says Stifel
VALE Vale
$11.43 /

+ (+0.00%)

PSTG Pure Storage
$18.11 /

+ (+0.00%)

PINS Pinterest
$36.07 /

+ (+0.00%)

MO Altria Group
$41.00 /

+ (+0.00%)

INTC Intel
$48.29 /

+ (+0.00%)

BP BP
$22.09 /

+ (+0.00%)

AZN AstraZeneca
$56.80 /

+ (+0.00%)

ARCC Ares Capital
$14.44 /

+ (+0.00%)

ADT ADT Inc.
$13.42 /

+ (+0.00%)

  • 16
    Oct
VALE Vale
$11.43 /

+ (+0.00%)

PSTG Pure Storage
$18.11 /

+ (+0.00%)

PINS Pinterest
$36.07 /

+ (+0.00%)

MO Altria Group
$41.00 /

+ (+0.00%)

INTC Intel
$48.29 /

+ (+0.00%)

BP BP
$22.09 /

+ (+0.00%)

AZN AstraZeneca
$56.80 /

+ (+0.00%)

VALE Vale
$11.43 /

+ (+0.00%)

PSTG Pure Storage
$18.11 /

+ (+0.00%)

PINS Pinterest
$36.07 /

+ (+0.00%)

MO Altria Group
$41.00 /

+ (+0.00%)

INTC Intel
$48.29 /

+ (+0.00%)

BP BP
$22.09 /

+ (+0.00%)

AZN AstraZeneca
$56.80 /

+ (+0.00%)

ADT ADT Inc.
$13.42 /

+ (+0.00%)

VALE Vale
$11.43 /

+ (+0.00%)

PSTG Pure Storage
$18.11 /

+ (+0.00%)

PINS Pinterest
$36.07 /

+ (+0.00%)

MO Altria Group
$41.00 /

+ (+0.00%)

INTC Intel
$48.29 /

+ (+0.00%)

BP BP
$22.09 /

+ (+0.00%)

AZN AstraZeneca
$56.80 /

+ (+0.00%)

ARCC Ares Capital
$14.44 /

+ (+0.00%)

ADT ADT Inc.
$13.42 /

+ (+0.00%)

Hot Stocks
Ideaya Biosciences announces HSR clearance of GlaxoSmithKline partnership » 06:14
08/04/20
08/04
06:14
08/04/20
06:14
IDYA

Ideaya Biosciences

$11.50 /

-1.09 (-8.66%)

, GSK

GlaxoSmithKline

$41.28 /

+0.975 (+2.42%)

Ideaya Biosciences…

Ideaya Biosciences announced the effectiveness of the collaboration, option and license agreement between the company and GlaxoSmithKline (GSK) following clearance under the Hart-Scott-Rodino Antitrust Improvements Act, or HSR. Pursuant to the agreement, Ideaya received an upfront cash payment of $100M from GSK. The strategic partnership in Synthetic Lethality includes Ideaya's MAT2A, Pol Theta, and Werner Helicase programs. Ideaya also announced closing of a direct private placement equity financing pursuant to a stock purchase agreement between Ideaya and Glaxo Group. Glaxo Group purchased 1,333,333 shares of Ideaya's common stock at a price per share of $15.00. Ideaya received proceeds from Glaxo Group of approximately $20M. Ideaya expects current cash, cash equivalents and marketable securities to support planned operations into 2024.

ShowHide Related Items >><<
IDYA Ideaya Biosciences
$11.50 /

-1.09 (-8.66%)

GSK GlaxoSmithKline
$41.28 /

+0.975 (+2.42%)

IDYA Ideaya Biosciences
$11.50 /

-1.09 (-8.66%)

07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
07/13/20 JPMorgan
Ideaya Biosciences upgraded to Overweight from Neutral at JPMorgan
06/17/20 H.C. Wainwright
Ideaya Biosciences price target raised to $22 from $13 at H.C. Wainwright
GSK GlaxoSmithKline
$41.28 /

+0.975 (+2.42%)

07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
IDYA Ideaya Biosciences
$11.50 /

-1.09 (-8.66%)

GSK GlaxoSmithKline
$41.28 /

+0.975 (+2.42%)

  • 18
    Jun
GSK GlaxoSmithKline
$41.28 /

+0.975 (+2.42%)

IDYA Ideaya Biosciences
$11.50 /

-1.09 (-8.66%)

GSK GlaxoSmithKline
$41.28 /

+0.975 (+2.42%)

IDYA Ideaya Biosciences
$11.50 /

-1.09 (-8.66%)

GSK GlaxoSmithKline
$41.28 /

+0.975 (+2.42%)

Monday
Recommendations
MorphoSys FDA approval in line with expectations, says Deutsche Bank » 13:27
08/03/20
08/03
13:27
08/03/20
13:27
MOR

MorphoSys

$34.24 /

+2.13 (+6.63%)

, INCY

Incyte

$101.14 /

+2.38 (+2.41%)

Deutsche Bank analyst…

Deutsche Bank analyst Rajan Sharma reiterated a Buy rating and EUR129 price target on MorphoSys (MOR) after the company and Incyte (INCY) announced conditional FDA approval of Fc-engineered CD19 antibody tafasitamab in combination with Revlimid for the treatment of relapsed/refractory diffuse large B-cell lymphoma ahead of its August 30 PDUFA data. The analyst said that approval is in line with his expectations.

ShowHide Related Items >><<
MOR MorphoSys
$34.24 /

+2.13 (+6.63%)

INCY Incyte
$101.14 /

+2.38 (+2.41%)

MOR MorphoSys
$34.24 /

+2.13 (+6.63%)

08/03/20 Piper Sandler
Monjuvi U.S. launch a solid long-term contributor for Incyte, says Piper Sandler
06/25/20 RBC Capital
MorphoSys downgraded to Sector Perform from Outperform at RBC Capital
05/13/20 Barclays
MorphoSys price target raised to EUR 105 from EUR 100 at Barclays
05/12/20 HSBC
MorphoSys upgraded to Hold from Reduce at HSBC
INCY Incyte
$101.14 /

+2.38 (+2.41%)

07/23/20 Stifel
Incyte REACH3 'nice incremental surprise,' not narrative-changing, says Stifel
07/23/20 Piper Sandler
Piper says Incyte cements 'all-around win for Jakafi' with REACH3 results
07/20/20 Credit Suisse
Incyte price target raised to $100 from $88 at Credit Suisse
MOR MorphoSys
$34.24 /

+2.13 (+6.63%)

INCY Incyte
$101.14 /

+2.38 (+2.41%)

MOR MorphoSys
$34.24 /

+2.13 (+6.63%)

MOR MorphoSys
$34.24 /

+2.13 (+6.63%)

INCY Incyte
$101.14 /

+2.38 (+2.41%)

INCY Incyte
$101.14 /

+2.38 (+2.41%)

Recommendations
Novo Nordisk price target lowered to DKK 425 from DKK 435 at Morgan Stanley » 12:02
08/03/20
08/03
12:02
08/03/20
12:02
NVO

Novo Nordisk

$65.81 /

+0.51 (+0.78%)

Morgan Stanley analyst…

Morgan Stanley analyst Mark Purcell lowered the firm's price target on Novo Nordisk to DKK 425 from DKK 435 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
NVO Novo Nordisk
$65.81 /

+0.51 (+0.78%)

NVO Novo Nordisk
$65.81 /

+0.51 (+0.78%)

07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
NVO Novo Nordisk
$65.81 /

+0.51 (+0.78%)

NVO Novo Nordisk
$65.81 /

+0.51 (+0.78%)

NVO Novo Nordisk
$65.81 /

+0.51 (+0.78%)

NVO Novo Nordisk
$65.81 /

+0.51 (+0.78%)

Recommendations
Monjuvi U.S. launch a solid long-term contributor for Incyte, says Piper Sandler » 11:10
08/03/20
08/03
11:10
08/03/20
11:10
INCY

Incyte

$100.16 /

+1.4 (+1.42%)

, MOR

MorphoSys

$33.96 /

+1.855 (+5.78%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren notes that Incyte (INCY) and partner MorphoSys (MOR) hosted a call on Monday to review the approval of Monjuvi. Based on management's comments, the analyst thinks the pricing is reasonable considering the observed treatment benefit, and continues to have confidence in the upcoming Monjuvi U.S. launch given the synergies that will likely be realized by leveraging Incyte's current Jakafi infrastructure and recent experience from the Pemazyre virtual drug launch. Recall that it is a 50/50 profit share in the U.S., so substantial profit likely won't be realized until next year, but still could be a meaningful $300M profit contributor long-term, he contends. Van Buren has an Overweight rating and a price target of $110 on Incyte's shares.

ShowHide Related Items >><<
MOR MorphoSys
$33.96 /

+1.855 (+5.78%)

INCY Incyte
$100.16 /

+1.4 (+1.42%)

INCY Incyte
$100.16 /

+1.4 (+1.42%)

07/23/20 Stifel
Incyte REACH3 'nice incremental surprise,' not narrative-changing, says Stifel
07/23/20 Piper Sandler
Piper says Incyte cements 'all-around win for Jakafi' with REACH3 results
07/20/20 Credit Suisse
Incyte price target raised to $100 from $88 at Credit Suisse
06/16/20
Fly Intel: Top five analyst initiations
MOR MorphoSys
$33.96 /

+1.855 (+5.78%)

06/25/20 RBC Capital
MorphoSys downgraded to Sector Perform from Outperform at RBC Capital
05/13/20 Barclays
MorphoSys price target raised to EUR 105 from EUR 100 at Barclays
05/12/20 HSBC
MorphoSys upgraded to Hold from Reduce at HSBC
03/25/20 Oppenheimer
Incyte price target lowered to $85 from $99 at Oppenheimer
MOR MorphoSys
$33.96 /

+1.855 (+5.78%)

INCY Incyte
$100.16 /

+1.4 (+1.42%)

MOR MorphoSys
$33.96 /

+1.855 (+5.78%)

MOR MorphoSys
$33.96 /

+1.855 (+5.78%)

INCY Incyte
$100.16 /

+1.4 (+1.42%)

INCY Incyte
$100.16 /

+1.4 (+1.42%)

Options
Unusually active option classes on open August 3rd » 09:40
08/03/20
08/03
09:40
08/03/20
09:40
EWJ

iShares MSCI Japan Index Fund

$54.34 /

+ (+0.00%)

, MOS

Mosaic

$13.48 /

+ (+0.00%)

, CLX

Clorox

$236.20 /

+ (+0.00%)

, GSK

GlaxoSmithKline

$40.31 /

+ (+0.00%)

, VALE

Vale

$11.63 /

+ (+0.00%)

, MSFT

Microsoft

$205.00 /

+ (+0.00%)

, RIOT

Riot Blockchain

$2.62 /

+ (+0.00%)

, UNG

United States Natural Gas Fund

$10.27 /

+ (+0.00%)

, JMIA

Jumia Technologies

$15.51 /

+ (+0.00%)

, MPC

Marathon Petroleum

$38.24 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: iShares Japan (EWJ), Mosaic (MOS), Clorox (CLX), GlaxoSmithKline (GSK), Vale (VALE), Microsoft (MSFT), Riot Blockchain (RIOT), U.S. Natural Gas Fund (UNG), Jumia Technologies (JMIA), and Marathon Petroleum (MPC).

ShowHide Related Items >><<
VALE Vale
$11.63 /

+ (+0.00%)

RIOT Riot Blockchain
$2.62 /

+ (+0.00%)

MSFT Microsoft
$205.00 /

+ (+0.00%)

MPC Marathon Petroleum
$38.24 /

+ (+0.00%)

MOS Mosaic
$13.48 /

+ (+0.00%)

JMIA Jumia Technologies
$15.51 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.31 /

+ (+0.00%)

CLX Clorox
$236.20 /

+ (+0.00%)

EWJ iShares MSCI Japan Index Fund
$54.34 /

+ (+0.00%)

MOS Mosaic
$13.48 /

+ (+0.00%)

07/15/20 Citi
Mosaic upgraded to Buy from Neutral at Citi
06/29/20
Fly Intel: Top five analyst upgrades
06/29/20 BofA
Mosaic upgraded to Buy from Underperform at BofA
05/11/20 BofA
Nutrien, Mosaic, Corteva, CF Industries cut to Underperform at BofA
CLX Clorox
$236.20 /

+ (+0.00%)

07/27/20 Deutsche Bank
Clorox price target raised to $223 from $174 at Deutsche Bank
07/16/20 JPMorgan
Clorox price target raised to $235 from $203 at JPMorgan
06/30/20 DA Davidson
Clorox initiated with a Buy at DA Davidson
06/29/20 DA Davidson
Clorox initiated with a Buy at DA Davidson
GSK GlaxoSmithKline
$40.31 /

+ (+0.00%)

07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
VALE Vale
$11.63 /

+ (+0.00%)

06/11/20 Deutsche Bank
Vale price target raised to $13 from $11 at Deutsche Bank
06/09/20 GLJ Research
Fortescue Metals upgraded to Hold from Sell at GLJ Research
06/05/20 Exane BNP Paribas
Vale upgraded to Outperform from Neutral at Exane BNP Paribas
06/03/20 UBS
Vale upgraded to Buy from Neutral at UBS
MSFT Microsoft
$205.00 /

+ (+0.00%)

08/03/20 Wedbush
Wedbush sees a TikTok deal as big bet from Microsoft on social media space
07/31/20 Stifel
Citrix disclosure points to $1B commitment, most likely to Azure, says Stifel
07/27/20 Morgan Stanley
Morgan Stanley downgrades Software industry view to In-Line from Attractive
07/23/20
Fly Intel: Top five analyst downgrades
RIOT Riot Blockchain
$2.62 /

+ (+0.00%)

UNG United States Natural Gas Fund
$10.27 /

+ (+0.00%)

JMIA Jumia Technologies
$15.51 /

+ (+0.00%)

05/14/20 Stifel
Jumia Technologies downgraded to Hold from Buy at Stifel
03/25/20 Berenberg
Jumia Technologies downgraded to Hold from Buy at Berenberg
02/26/20 RBC Capital
Jumia Technologies price target lowered to $13 from $22 at RBC Capital
02/25/20 Stifel
Jumia Technologies price target lowered to $8 from $10 at Stifel
MPC Marathon Petroleum
$38.24 /

+ (+0.00%)

08/03/20 Morgan Stanley
Marathon sale of Speedway for $21B a 'positive outcome,' says Morgan Stanley
07/15/20 Morgan Stanley
MPLX downgraded to Equal Weight from Overweight at Morgan Stanley
05/13/20 Morgan Stanley
U.S. gasoline consumption appears to have bottomed, says Morgan Stanley
04/24/20 Citi
Marathon Petroleum downgraded to Neutral from Buy at Citi
VALE Vale
$11.63 /

+ (+0.00%)

MSFT Microsoft
$205.00 /

+ (+0.00%)

MPC Marathon Petroleum
$38.24 /

+ (+0.00%)

MOS Mosaic
$13.48 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.31 /

+ (+0.00%)

CLX Clorox
$236.20 /

+ (+0.00%)

VALE Vale
$11.63 /

+ (+0.00%)

MSFT Microsoft
$205.00 /

+ (+0.00%)

MPC Marathon Petroleum
$38.24 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.31 /

+ (+0.00%)

CLX Clorox
$236.20 /

+ (+0.00%)

VALE Vale
$11.63 /

+ (+0.00%)

RIOT Riot Blockchain
$2.62 /

+ (+0.00%)

MSFT Microsoft
$205.00 /

+ (+0.00%)

MPC Marathon Petroleum
$38.24 /

+ (+0.00%)

MOS Mosaic
$13.48 /

+ (+0.00%)

JMIA Jumia Technologies
$15.51 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.31 /

+ (+0.00%)

CLX Clorox
$236.20 /

+ (+0.00%)

VALE Vale
$11.63 /

+ (+0.00%)

UNG United States Natural Gas Fund
$10.27 /

+ (+0.00%)

RIOT Riot Blockchain
$2.62 /

+ (+0.00%)

MSFT Microsoft
$205.00 /

+ (+0.00%)

MPC Marathon Petroleum
$38.24 /

+ (+0.00%)

MOS Mosaic
$13.48 /

+ (+0.00%)

JMIA Jumia Technologies
$15.51 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.31 /

+ (+0.00%)

EWJ iShares MSCI Japan Index Fund
$54.34 /

+ (+0.00%)

CLX Clorox
$236.20 /

+ (+0.00%)

MSFT Microsoft
$205.00 /

+ (+0.00%)

EWJ iShares MSCI Japan Index Fund
$54.34 /

+ (+0.00%)

Recommendations
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies » 06:55
08/03/20
08/03
06:55
08/03/20
06:55
MRNA

Moderna

$74.10 /

-3.5 (-4.51%)

, PFE

Pfizer

$38.48 /

-0.27 (-0.70%)

, BNTX

BioNTech

$82.12 /

-1.895 (-2.26%)

, AZN

AstraZeneca

$55.77 /

-2.13 (-3.68%)

Jefferies analyst Michael…

Jefferies analyst Michael Yee said he sees fast enrollment in the Phase 3 study of Moderna's (MRNA) COVID-19 vaccine, along with above-average infection rates in U.S. hot spots, leaving 70% odds that the trial could meet its primary endpoint before the end of October to early November based on the first or second interim. Yee believes Moderna's Phase 3 trial has a 65% chance of working and with data coming potentially as soon as October he thinks emergency use authorization approval is potentially possible by the end of 2020. He sees similar, if not earlier into September, timing for the vaccine candidate being studied by Pfizer (PFE) and BioNTech (BNTX), due to global enrollment and other minor details, Yee added. He also estimates Oxford and AstraZeneca's (AZN) data may read out by Fall given more EU based enrollment and infection rate sensitivities, the analyst noted.

ShowHide Related Items >><<
PFE Pfizer
$38.48 /

-0.27 (-0.70%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

BNTX BioNTech
$82.12 /

-1.895 (-2.26%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/27/20 Piper Sandler
Piper reiterates $134 Moderna target on start of Phase III vaccine trial
07/27/20 BMO Capital
Moderna price target lowered to $94 from $112 at BMO Capital
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
PFE Pfizer
$38.48 /

-0.27 (-0.70%)

07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
BNTX BioNTech
$82.12 /

-1.895 (-2.26%)

07/21/20
Fly Intel: Top five analyst upgrades
07/21/20 Canaccord
BioNTech price target raised to $97 from $75 at Canaccord
AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
PFE Pfizer
$38.48 /

-0.27 (-0.70%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

BNTX BioNTech
$82.12 /

-1.895 (-2.26%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

  • 23
    Jul
  • 19
    May
  • 12
    Feb
  • 06
    Feb
  • 10
    Oct
PFE Pfizer
$38.48 /

-0.27 (-0.70%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

BNTX BioNTech
$82.12 /

-1.895 (-2.26%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

BNTX BioNTech
$82.12 /

-1.895 (-2.26%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

BNTX BioNTech
$82.12 /

-1.895 (-2.26%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

Sunday
Hot Stocks
Xencor earns milestone payment from MorphoSys for FDA approval of Monjuvi » 14:22
08/02/20
08/02
14:22
08/02/20
14:22
XNCR

Xencor

$30.02 /

-1.69 (-5.33%)

, MOR

MorphoSys

$32.11 /

-0.715 (-2.18%)

, INCY

Incyte

$98.76 /

-1.63 (-1.62%)

Xencor (XNCR) announced…

Xencor (XNCR) announced that the U.S. Food and Drug Administration approved MorphoSys' (MOR) Monjuvi, a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant. The most common adverse reactions are neutropenia, fatigue, anemia, diarrhea, thrombocytopenia, cough, pyrexia, peripheral edema, respiratory tract infection, and decreased appetite. Xencor has earned a $25M milestone payment from MorphoSys under the license agreement between the companies for Monjuvi in connection with the regulatory approval. Xencor licensed exclusive worldwide rights to develop and commercialize Monjuvi, product code MOR208 and previously XmAb5574, to MorphoSys in 2010. Monjuvi incorporates Xencor's XmAb engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis. Xencor is eligible to receive royalties on worldwide net sales in the high-single to low-double digit percent range and additional development, regulatory and sales milestone payments. Monjuvi will be co-commercialized in the U.S. by MorphoSys and Incyte (INCY). The European Marketing Authorization Application for tafasitamab, based on data from the L-MIND study and supported by the Re-MIND observational retrospective study, is currently under review by the European Medicines Agency.

ShowHide Related Items >><<
XNCR Xencor
$30.02 /

-1.69 (-5.33%)

MOR MorphoSys
$32.11 /

-0.715 (-2.18%)

INCY Incyte
$98.76 /

-1.63 (-1.62%)

XNCR Xencor
$30.02 /

-1.69 (-5.33%)

07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
06/22/20 Piper Sandler
Xencor's '2+1' biospecific antibodies ideal for solid tumors, says Piper Sandler
05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
MOR MorphoSys
$32.11 /

-0.715 (-2.18%)

06/25/20 RBC Capital
MorphoSys downgraded to Sector Perform from Outperform at RBC Capital
05/13/20 Barclays
MorphoSys price target raised to EUR 105 from EUR 100 at Barclays
05/12/20 HSBC
MorphoSys upgraded to Hold from Reduce at HSBC
03/25/20 Oppenheimer
Incyte price target lowered to $85 from $99 at Oppenheimer
INCY Incyte
$98.76 /

-1.63 (-1.62%)

07/23/20 Stifel
Incyte REACH3 'nice incremental surprise,' not narrative-changing, says Stifel
07/23/20 Piper Sandler
Piper says Incyte cements 'all-around win for Jakafi' with REACH3 results
07/20/20 Credit Suisse
Incyte price target raised to $100 from $88 at Credit Suisse
06/16/20
Fly Intel: Top five analyst initiations
XNCR Xencor
$30.02 /

-1.69 (-5.33%)

MOR MorphoSys
$32.11 /

-0.715 (-2.18%)

INCY Incyte
$98.76 /

-1.63 (-1.62%)

MOR MorphoSys
$32.11 /

-0.715 (-2.18%)

XNCR Xencor
$30.02 /

-1.69 (-5.33%)

MOR MorphoSys
$32.11 /

-0.715 (-2.18%)

INCY Incyte
$98.76 /

-1.63 (-1.62%)

INCY Incyte
$98.76 /

-1.63 (-1.62%)

Hot Stocks
MorphoSys announces FDA approval of Monjuvi, Lenalidomide combo » 14:17
08/02/20
08/02
14:17
08/02/20
14:17
INCY

Incyte

$98.76 /

-1.63 (-1.62%)

, MOR

MorphoSys

$32.11 /

-0.715 (-2.18%)

MorphoSys (MOR) announced…

MorphoSys (MOR) announced that the U.S. Food and Drug Administration has approved Monjuvi in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant. Monjuvi, a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, has been approved under accelerated approval by the U.S. FDA based on overall response rate. Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial or trials. The FDA decision represents the first approval of a second-line treatment for adult patients who progressed during or after first-line therapy. The FDA approval was based on data from the MorphoSys-sponsored Phase 2 L-MIND study, an open label, multicenter, single arm trial of Monjuvi in combination with lenalidomide as a treatment for adult patients with relapsed or refractory DLBCL. The FDA previously granted Fast Track and Breakthrough Therapy Designation for this combination in relapsed or refractory DLBCL, and the Biologics License Application for Monjuviwas granted Priority Review and approved under the FDA's Accelerated Approval program. Monjuvi is expected to be commercially available in the United States shortly. MorphoSys and its partner Incyte (INCY) will co-commercialize Monjuvi in the United States. Incyte has exclusive commercialization rights outside the United States.

ShowHide Related Items >><<
MOR MorphoSys
$32.11 /

-0.715 (-2.18%)

INCY Incyte
$98.76 /

-1.63 (-1.62%)

INCY Incyte
$98.76 /

-1.63 (-1.62%)

07/23/20 Stifel
Incyte REACH3 'nice incremental surprise,' not narrative-changing, says Stifel
07/23/20 Piper Sandler
Piper says Incyte cements 'all-around win for Jakafi' with REACH3 results
07/20/20 Credit Suisse
Incyte price target raised to $100 from $88 at Credit Suisse
06/16/20
Fly Intel: Top five analyst initiations
MOR MorphoSys
$32.11 /

-0.715 (-2.18%)

06/25/20 RBC Capital
MorphoSys downgraded to Sector Perform from Outperform at RBC Capital
05/13/20 Barclays
MorphoSys price target raised to EUR 105 from EUR 100 at Barclays
05/12/20 HSBC
MorphoSys upgraded to Hold from Reduce at HSBC
03/25/20 Oppenheimer
Incyte price target lowered to $85 from $99 at Oppenheimer
MOR MorphoSys
$32.11 /

-0.715 (-2.18%)

INCY Incyte
$98.76 /

-1.63 (-1.62%)

MOR MorphoSys
$32.11 /

-0.715 (-2.18%)

MOR MorphoSys
$32.11 /

-0.715 (-2.18%)

INCY Incyte
$98.76 /

-1.63 (-1.62%)

INCY Incyte
$98.76 /

-1.63 (-1.62%)

Conference/Events
Society for Robotic Surgery to hold a virtual symposium » 04:55
08/02/20
08/02
04:55
08/02/20
04:55
BDX

Becton Dickinson

$281.26 /

+7.205 (+2.63%)

, CNMD

Conmed

$82.46 /

-4.87 (-5.58%)

, EXAS

Exact Sciences

$94.76 /

-3.1 (-3.17%)

, TFX

Teleflex

$372.64 /

-11.37 (-2.96%)

, PCRX

Pacira

$52.62 /

-0.45 (-0.85%)

World Robotic Virtual…

World Robotic Virtual Symposium 2020 will be held on July 30-August 2. Webcast Link

ShowHide Related Items >><<
TFX Teleflex
$372.64 /

-11.37 (-2.96%)

PCRX Pacira
$52.62 /

-0.45 (-0.85%)

EXAS Exact Sciences
$94.76 /

-3.1 (-3.17%)

CNMD Conmed
$82.46 /

-4.87 (-5.58%)

BDX Becton Dickinson
$281.26 /

+7.205 (+2.63%)

BDX Becton Dickinson
$281.26 /

+7.205 (+2.63%)

07/09/20
Fly Intel: Top five analyst upgrades
07/09/20 Barclays
Barclays upgrades Becton Dickinson to Overweight on 'window of opportunity'
07/09/20 Barclays
Becton Dickinson upgraded to Overweight from Equal Weight at Barclays
07/02/20 Wells Fargo
Becton rallies after Wells says rapid COVID test may come very soon
CNMD Conmed
$82.46 /

-4.87 (-5.58%)

07/29/20 Piper Sandler
Conmed price target raised to $95 from $90 at Piper Sandler
04/30/20 Piper Sandler
Conmed price target lowered to $90 from $110 at Piper Sandler
04/20/20 Piper Sandler
Conmed news positive for company, entire sector, says Piper Sandler
03/20/20 Piper Sandler
Conmed results to bounce back 'fairly quickly,' says Piper Sandler
EXAS Exact Sciences
$94.76 /

-3.1 (-3.17%)

07/31/20 Benchmark
Exact Sciences price target raised to $110 from $90 at Benchmark
07/31/20 Citi
Exact Sciences price target raised to $120 from $110 at Citi
07/23/20 Evercore ISI
Evercore ISI says Humana pact relates to FIT testing, not Exact's Cologuard
07/23/20 Evercore ISI
Humana plans could boost Exact's growth as much as 12%, says Evercore ISI
TFX Teleflex
$372.64 /

-11.37 (-2.96%)

07/30/20 Piper Sandler
Teleflex selloff on DOJ investigation should be bought, says Piper Sandler
06/09/20 Wells Fargo
Teleflex price target raised to $425 from $375 at Wells Fargo
06/04/20 SVB Leerink
Teleflex price target raised to $425 from $400 at SVB Leerink
05/01/20 Piper Sandler
Teleflex price target lowered to $375 from $425 at Piper Sandler
PCRX Pacira
$52.62 /

-0.45 (-0.85%)

07/13/20 H.C. Wainwright
Pacira price target raised to $68 from $63 at H.C. Wainwright
07/10/20 Jefferies
Pacira price target raised to $69 from $53 at Jefferies
07/06/20 Needham
Pacira price target raised to $64 from $52 at Needham
07/06/20 Piper Sandler
Pacira price target raised to $65 from $49 at Piper Sandler
TFX Teleflex
$372.64 /

-11.37 (-2.96%)

PCRX Pacira
$52.62 /

-0.45 (-0.85%)

EXAS Exact Sciences
$94.76 /

-3.1 (-3.17%)

CNMD Conmed
$82.46 /

-4.87 (-5.58%)

BDX Becton Dickinson
$281.26 /

+7.205 (+2.63%)

  • 21
    May
PCRX Pacira
$52.62 /

-0.45 (-0.85%)

EXAS Exact Sciences
$94.76 /

-3.1 (-3.17%)

BDX Becton Dickinson
$281.26 /

+7.205 (+2.63%)

EXAS Exact Sciences
$94.76 /

-3.1 (-3.17%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.